Lab21 Sells SC Labs, Assets Acquired by Selah Genomics | GenomeWeb

NEW YORK (GenomeWeb News) – The Cambridge, UK-based personalized diagnostics company Lab 21 said today that it has sold its lab operations in South Carolina to a new entity formed by existing local Lab21 executives who will launch a new company called Selah Genomics.

The sale of the clinical service lab operations in Greenville and Columbia, which Lab21 has run for three years, will remove a loss-making business from the company's books, but will not impact the company's core strategies in the US market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of 200 bird species, and more.

The Australian High Court rules that isolated genetic material cannot be patented.

The startup incubator Y Combinator is launching a nonprofit research lab.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.

Sponsored by

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Sponsored by

This webinar will focus on a range of research and clinical applications enabled by improvements in mate pair technology for whole genome sequencing. 

Sponsored by
Oracle Health Sciences

Brian Wells of Penn Medicine will detail how his team's "PennOmics" integrated healthcare data warehouse accelerates clinical trial recruitment at the point of care, accepts data from wearables, and does it all in a secure, HIPAA- and research-compliant fashion.